Inhaled Umeclidinium in COPD Patients: A Review and Meta-Analysis

Overview

Journal Drugs

Specialty Pharmacology

Date 2016 Jan 13

PMID 26755180

Citations 11

Authors

Roy A Pleasants

Tiansheng Wang

Jinming Gao

Huilin Tang

James F Donohue

Affiliations

Soon will be listed here.

Abstract

A number of new agents for the management of chronic obstructive pulmonary disease (COPD) are at different stages of development, including several inhaled long-acting antimuscarinics (LAMA). Long-acting bronchodilators are considered to be central to the management of COPD due to the evidence supporting their efficacy and safety. Umeclidinium, a LAMA, has recently been approved for the maintenance treatment of moderate to very severe COPD in a number of countries. This comprehensive review and pooled meta-analysis provides detailed information about the efficacy and safety of this agent. The pharmacokinetics and pharmacodynamics of umeclidinium observed in phase I and II studies support its once-daily administration. Umeclidinium is rapidly cleared from blood, and renal or hepatic impairment do not lead to significant changes in drug disposition. A pooled analysis of phase III and comparative studies of umeclidinium in patients with moderate to very severe COPD showed significant improvement in lung function measures, including trough forced expiratory volume in 1 s (FEV1), as well as in acute exacerbations of COPD, dyspnea, and quality of life. Adverse effects, including known anticholinergic effects, were uncommon with umeclidinium. Limited data suggest the efficacy of umeclidinium is similar to that of tiotropium. Umeclidinium is administered as a dry powder inhaler, provides adequate lung delivery in patients with moderate to very severe airflow obstruction, and appears to be easily used by patients. Umeclidinium provides a safe and effective option as an inhaled LAMA for the management of COPD.

Citing Articles

Real-world effects of once-daily inhaled steroid (fluticasone furoate) combined with long-acting beta-2 agonist (vilanterol) and long-acting muscarinic antagonist (umeclidinium) on lung function tests of asthma patients in Japan.

Umeda A, Shimada H, Yamane T, Mochizuki T, Inoue Y, Tsushima K Front Physiol. 2023; 14:1131949.

PMID: 37179838 PMC: 10170765. DOI: 10.3389/fphys.2023.1131949.

The Utilization and Safety of Umeclidinium and Umeclidinium/Vilanterol in UK Primary Care: A Retrospective Cohort Study.

Requena G, Dedman D, Quint J, Ghosh R, Williams R, Pimenta J Int J Chron Obstruct Pulmon Dis. 2021; 16:629-642.

PMID: 33731992 PMC: 7956862. DOI: 10.2147/COPD.S291931.

Evidence-based review of data on the combination inhaler umeclidinium/vilanterol in patients with COPD.

Albertson T, Bowman W, Harper R, Godbout R, Murin S Int J Chron Obstruct Pulmon Dis. 2019; 14:1251-1265.

PMID: 31239659 PMC: 6559138. DOI: 10.2147/COPD.S191845.

Effect of triple therapy in patients with asthma-COPD overlap .

Ishiura Y, Fujimura M, Ohkura N, Hara J, Kasahara K, Ishii N Int J Clin Pharmacol Ther. 2019; 57(8):384-392.

PMID: 31232275 PMC: 6637394. DOI: 10.5414/CP203382.

Fixed-Dose Combinations of Long-Acting Bronchodilators for the Management of COPD: Global and Asian Perspectives.

Rhee C, Yoshisue H, Lad R Adv Ther. 2019; 36(3):495-519.

PMID: 30742242 PMC: 6824447. DOI: 10.1007/s12325-019-0893-3.

References

Bateman E, Rennard S, Barnes P, Dicpinigaitis P, Gosens R, Gross N . Alternative mechanisms for tiotropium. Pulm Pharmacol Ther. 2009; 22(6):533-42. DOI: 10.1016/j.pupt.2009.06.002. View

Trivedi R, Richard N, Mehta R, Church A . Umeclidinium in patients with COPD: a randomised, placebo-controlled study. Eur Respir J. 2013; 43(1):72-81. DOI: 10.1183/09031936.00033213. View

Belmonte K . Cholinergic pathways in the lungs and anticholinergic therapy for chronic obstructive pulmonary disease. Proc Am Thorac Soc. 2005; 2(4):297-304. DOI: 10.1513/pats.200504-043SR. View

Kelleher D, Tombs L, Preece A, Brealey N, Mehta R . A randomized, placebo- and moxifloxacin-controlled thorough QT study of umeclidinium monotherapy and umeclidinium/vilanterol combination in healthy subjects. Pulm Pharmacol Ther. 2014; 29(1):49-57. DOI: 10.1016/j.pupt.2014.07.002. View

Church A, Beerahee M, Brooks J, Mehta R, Shah P . Dose response of umeclidinium administered once or twice daily in patients with COPD: a randomised cross-over study. BMC Pulm Med. 2014; 14:2. PMC: 4029330. DOI: 10.1186/1471-2466-14-2. View

Kelleher D, Mehta R, Jean-Francois B, Preece A, Blowers J, Crater G . Safety, tolerability, pharmacodynamics and pharmacokinetics of umeclidinium and vilanterol alone and in combination: a randomized crossover trial. PLoS One. 2013; 7(12):e50716. PMC: 3524248. DOI: 10.1371/journal.pone.0050716. View

Hu C, Jia J, Dong K, Luo L, Wu K, Mehta R . Pharmacokinetics and tolerability of inhaled umeclidinium and vilanterol alone and in combination in healthy Chinese subjects: a randomized, open-label, crossover trial. PLoS One. 2015; 10(3):e0121264. PMC: 4376748. DOI: 10.1371/journal.pone.0121264. View

Prime D, De Backer W, Hamilton M, Cahn A, Preece A, Kelleher D . Effect of Disease Severity in Asthma and Chronic Obstructive Pulmonary Disease on Inhaler-Specific Inhalation Profiles Through the ELLIPTA® Dry Powder Inhaler. J Aerosol Med Pulm Drug Deliv. 2015; 28(6):486-97. PMC: 4685483. DOI: 10.1089/jamp.2015.1224. View

Donohue J, Anzueto A, Brooks J, Mehta R, Kalberg C, Crater G . A randomized, double-blind dose-ranging study of the novel LAMA GSK573719 in patients with COPD. Respir Med. 2012; 106(7):970-9. DOI: 10.1016/j.rmed.2012.03.012. View

10.

Grant A, Walker R, Hamilton M, Garrill K . The ELLIPTA® Dry Powder Inhaler: Design, Functionality, In Vitro Dosing Performance and Critical Task Compliance by Patients and Caregivers. J Aerosol Med Pulm Drug Deliv. 2015; 28(6):474-85. PMC: 4685506. DOI: 10.1089/jamp.2015.1223. View

11.

Salmon M, Luttmann M, Foley J, Buckley P, Schmidt D, Burman M . Pharmacological characterization of GSK573719 (umeclidinium): a novel, long-acting, inhaled antagonist of the muscarinic cholinergic receptors for treatment of pulmonary diseases. J Pharmacol Exp Ther. 2013; 345(2):260-70. DOI: 10.1124/jpet.112.202051. View

12.

Hoppentocht M, Hagedoorn P, Frijlink H, de Boer A . Technological and practical challenges of dry powder inhalers and formulations. Adv Drug Deliv Rev. 2014; 75:18-31. DOI: 10.1016/j.addr.2014.04.004. View

13.

Mehta R, Hardes K, Kelleher D, Preece A, Tombs L, Brealey N . Effects of moderate hepatic impairment on the pharmacokinetic properties and tolerability of umeclidinium and vilanterol in inhalational umeclidinium monotherapy and umeclidinium/vilanterol combination therapy: an open-label, nonrandomized study. Clin Ther. 2014; 36(7):1016-1027.e2. DOI: 10.1016/j.clinthera.2014.05.002. View

14.

Barnes P . Distribution of receptor targets in the lung. Proc Am Thorac Soc. 2005; 1(4):345-51. DOI: 10.1513/pats.200409-045MS. View

15.

Decramer M, Maltais F, Feldman G, Brooks J, Harris S, Mehta R . Bronchodilation of umeclidinium, a new long-acting muscarinic antagonist, in COPD patients. Respir Physiol Neurobiol. 2012; 185(2):393-9. DOI: 10.1016/j.resp.2012.08.022. View

16.

Rhoden K, Meldrum L, Barnes P . Inhibition of cholinergic neurotransmission in human airways by beta 2-adrenoceptors. J Appl Physiol (1985). 1988; 65(2):700-5. DOI: 10.1152/jappl.1988.65.2.700. View

17.

Canning B, Fischer A . Neural regulation of airway smooth muscle tone. Respir Physiol. 2001; 125(1-2):113-27. DOI: 10.1016/s0034-5687(00)00208-5. View

18.

Svedsater H, Dale P, Garrill K, Walker R, Woepse M . Qualitative assessment of attributes and ease of use of the ELLIPTA™ dry powder inhaler for delivery of maintenance therapy for asthma and COPD. BMC Pulm Med. 2013; 13:72. PMC: 4029771. DOI: 10.1186/1471-2466-13-72. View

19.

Kesler B, Canning B . Regulation of baseline cholinergic tone in guinea-pig airway smooth muscle. J Physiol. 1999; 518 ( Pt 3):843-55. PMC: 2269456. DOI: 10.1111/j.1469-7793.1999.0843p.x. View

20.

Hamilton M, Leggett R, Pang C, Charles S, Gillett B, Prime D . In Vitro Dosing Performance of the ELLIPTA® Dry Powder Inhaler Using Asthma and COPD Patient Inhalation Profiles Replicated with the Electronic Lung (eLung™). J Aerosol Med Pulm Drug Deliv. 2015; 28(6):498-506. PMC: 4685503. DOI: 10.1089/jamp.2015.1225. View